Postmenopausal Breast Cancer
Studies find aromatase inhibitors (AIs) and bisphosphonates improve survival in postmenopausal breast cancer patientsAugust 13, 2015
Two new studies suggest that two different classes of drugs, aromatase inhibitors (AIs) and bisphosphonates, can each improve survival prospects for postmenopausal women with early breast cancer.
Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced with the antihormone therapy anastrozole, according to the initial results of a double-blind, randomized, placebo-controlled trial presented at the 2013 San Antonio Breast Cancer Symposium.
Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.
Black women have the highest death rate from breast cancer of all racial and ethnic groups, and are 40% more likely to die of the disease than are white women, according to a new report from the CDC.
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
Women who receive aromatase inhibitors for breast cancer after menopause experience very high levels of sexual difficulties, including low interest, insufficient lubrication, and pain with intercourse, according to a recent study.
Most older women with early breast cancer are more likely to avoid mastectomy by following lumpectomy with radiation, contrary to current thinking.
Overweight women with breast cancer were found to have more estrogen remaining after hormone-suppressing therapy than did women of healthy weight.
Accelerated external-beam radiotherapy is a viable treatment option for ductal carcinoma in situ (DCIS), suggest recent study results.
Overall US cancer death rates have continued to decline since the early 1990s, but excess weight and lack of sufficient activity contribute to the increased incidence of many cancers.
Cognitive deficits subsequent to breast cancer chemotherapy using cyclophosphamide, methotrexate, and fluorouracil can be long-lasting.
Many women who underwent accelerated partial breast irradiation using brachytherapy were deemed cautionary or unsuitable for the procedure based on guidelines later issued by ASTRO.
Preoperative breast-imaging claims on multiple dates have been increasing substantially since 1992, suggesting that the patient's time burden for such evaluation has also been increasing.
Age should not be a contraindication for breast reconstruction in elderly women, data from a retrospective chart review indicate.
Although popular among older women with breast cancer, accelerated partial breast brachytherapy may be less effective and more toxic than standard whole breast irradiation in these patients.
Administering anastrozole (Arimidex) and fulvestrant (Faslodex) in combination rather than in sequence extended overall survival by 6 months in women with metastatic breast cancer, researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.
The Canadian Task Force on Preventive Health Care is advising against routine mammography screening for women aged 40 to 49 and says to screen women aged 50 to 74 every 2 to 3 years.
Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.
A large study has found that the routine use of zoledronic acid in the adjuvant management of breast cancer is not beneficial, but might extend survival in a subset of postmenopausal women.
Women 60 years and older who received no systemic adjuvant therapy for early-stage breast tumors were at no greater mortality risk than similarly aged women in the general population.
A key health care database may not be accurately reflecting the use of radiation treatments after breast-conserving surgery among breast cancer patients, indicates a recent analysis.
A study of everolimus plus exemestane in metastatic breast cancer ended early, after an interim analysis revealed that the regimen significantly extended progression-free survival.
Recommendations on how often a woman should undergo mammography screening should be personalized based on various risk factors, say researchers estimating the cost-effectiveness of mammography.
A significant portion of women who develop invasive breast cancer have no family history of the disease, indicating that other relevant factors should also be considered.
Adjuvant use of zoledronic acid did not improve disease-free survival in women with stage II/III breast cancer treated with adjuvant chemotherapy, concluded AZURE trial.
Overweight and obesity were responsible for 124,000 new cancers in Europe in 2008, the results of a modelling study suggest. The proportion of new cancers attributable to a BMI of 25kg/m2 or more was highest among women and in central European countries.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|